US FDA OKs Korean neutropenia treatment drug
Published: 2009-10-16 06:56:00
Updated: 2009-10-16 06:56:00
Hanmi Pharm said it has received approval from the U.S. Food and Drug Administration to conduct Phase 1 clinical trial of LAPS-GCSF (HM10460A, a drug for the treatment of neutropenia, following an approval on novel erythropoietin.
Lapscovery technology using Hanmi’s novel recombinant carrier e...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
